Drug profile

The FDA adverse-event record for Milbemycin Oxime/ Spinosad

11 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Milbemycin Oxime/ Spinosad. See the species affected, top reactions, and outcomes below.

11
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
3
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Milbemycin Oxime/ Spinosad

Administration Routes

Oral

Species Affected

Dog 11

Most Affected Breeds

Shih Tzu 3
Shepherd Dog - German 1
Terrier - Boston 1
Terrier - Yorkshire 1
Pug 1
Dog (other) 1
Schnauzer - Miniature 1
Terrier - Irish Soft-coated Wheaten 1
Bulldog 1

Most Reported Reactions

Vomiting 3
Other abnormal test result NOS 3
Diarrhoea 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Elevated alanine aminotransferase (ALT) 2
Emesis 2
INEFFECTIVE, HEARTWORM LARVAE 1
INEFFECTIVE, ASCARIDS NOS 1
Anaemia NOS 1
Pale mucous membrane 1
Jaw disorder 1
Chronic renal failure 1

Outcome Breakdown

Recovered/Normal
7 (63.6%)
Ongoing
3 (27.3%)
Outcome Unknown
1 (9.1%)

Milbemycin Oxime/ Spinosad Adverse Event Insights

11 reports name Milbemycin Oxime/ Spinosad; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Milbemycin Oxime/ Spinosad. Administration route: Oral.

By species: Dog (11 reports). By breed: Shih Tzu (3), Shepherd Dog - German (1), Terrier - Boston (1).

Leading clinical signs: Vomiting (3), Other abnormal test result NOS (3), Diarrhoea (2), Lethargy (see also Central nervous system depression in 'Neurological') (2). Outcome, 11 coded reports: Recovered/Normal leads at 63.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.